Research Use Only Notice: This article is intended only for qualified laboratory researchers. It discusses sermorelin as a research material for cell-based assays, receptor studies, enzyme studies, and analytical testing.
It does not provide human or veterinary dosing, administration, diagnostic, treatment, cosmetic, or personal-use instructions.
Sermorelin is a synthetic peptide made from the first 29 amino acids of human growth hormone-releasing hormone, or GHRH. The peptide has an amide group at its C-terminus and is often written as GHRH(1-29)-NH2.

It is mainly used in laboratory studies of the GHRH receptor, cell signaling, peptide breakdown, and peptide quality testing.[1]
Molecular Identity
| Property | Reference Information |
|---|---|
| Name | Sermorelin; human GHRH(1-29)-NH2 |
| One-letter sequence | YADAIFTNSYRKVLGQLSARKLLQDIMSR-NH2 |
| Three-letter sequence | H-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2 |
| Number of residues | 29 amino acids |
| Free-peptide formula | C149H246N44O42S |
| Free-peptide average molecular weight | Approximately 3,357.9 g/mol |
| Free-peptide monoisotopic mass | 3,355.8187 Da[1] |
| Free-peptide exact mass | 3,356.8221 Da[1] |
| Free-peptide CAS number | 86168-78-7 |
| C-terminal form | Amidated, -NH2 |
The formula, average molecular weight, monoisotopic mass, exact mass, and CAS number above refer to PubChem’s non-salt parent-compound record. The peptide’s protonation state and net charge in solution depend on pH; the experimental isoelectric point of sermorelin is approximately 9.99.[1]
Sermorelin acetate is a different chemical record because it includes acetate. One PubChem record for the 1:1 acetate form lists the formula C151H250N44O44S, an average molecular weight of about 3,417.9 g/mol, a monoisotopic mass of 3,415.8398 Da, an exact mass of 3,416.8432 Da, and CAS number 114466-38-5.[2]
Actual research batches may contain different amounts of acetate, water, or other counterions. The batch certificate of analysis should therefore be used when calculating the amount of peptide in a sample.
Activity in Laboratory Models
Sermorelin is an active N-terminal fragment of human GHRH, but it should not be described as having exactly the same potency as full-length GHRH in every experiment. In one study by Ling et al. using cultured rat anterior pituitary cells, GHRH(1-29)-NH2 showed full intrinsic activity but about half the potency of the longer GHRH(1-44)-NH2 reference peptide under the tested conditions.[3]
This difference is important because potency values depend on the test system. Results can change with the cell type, receptor level, incubation time, test method, and data-analysis method.
An EC50 value from one study should not be presented as a fixed value for all laboratories.
The GHRH receptor is a seven-transmembrane G-protein-coupled receptor in the secretin receptor family. Gaylinn et al. cloned and expressed the human anterior pituitary GHRH receptor and found that GHRH binding to this receptor increased intracellular cAMP.[4]
GHRH signaling can also affect calcium movement in pituitary-cell models. Lussier et al. used purified rat somatotrophs loaded with the fluorescent Ca2+ indicator indo-1 and found that GRF produced a concentration-related biphasic increase in free intracellular Ca2+ ([Ca2+]i).
Both the GRF-dependent [Ca2+]i increase and GH release were blocked by incubation in low-Ca2+ medium and by the organic Ca2+ antagonists nifedipine and diltiazem. Direct 45Ca uptake measurements under both steady-state and non-steady-state conditions confirmed that GRF stimulates Ca2+ influx into somatotrophs, while no redistribution of intracellularly stored Ca2+ was detected.[5]
These results came from cultured rat cells and should not be presented as direct evidence of effects in people.
DPP-IV Breakdown
Sermorelin starts with the amino-acid sequence Tyr-Ala-Asp. Dipeptidyl peptidase IV, usually shortened to DPP-IV or DPP-4, can remove the first two amino acids by cutting between Ala2 and Asp3.
This produces the shorter fragment GHRH(3-29)-NH2. Frohman et al. demonstrated this cleavage in human plasma and with purified DPP-IV.[6]
Purified-enzyme studies by Bongers et al. also confirmed that GHRH(1-29)-NH2 is a DPP-IV substrate, with kinetic analysis showing the Ala2-Asp3 bond as the primary cleavage site.[7] However, the breakdown rate is not the same in every experiment.
It depends on the enzyme source, enzyme activity, peptide concentration, buffer, pH, temperature, sample type, and test method.
For this reason, the article does not assign sermorelin a fixed DPP-IV half-life. A half-life should be calculated from data collected under the exact conditions used in the experiment.
Common Research Uses
- GHRH receptor assays: measuring receptor binding, cAMP changes, or another validated cell response.
- Structure-activity studies: comparing sermorelin with peptides that have changed amino acids or terminal groups.
- Enzyme-degradation studies: measuring intact peptide and breakdown products after exposure to DPP-IV or another enzyme.
- Pituitary-cell research: studying GHRH-related signaling in a clearly identified cell or tissue model.
- Analytical method development: testing HPLC, LC-MS, peptide mapping, or stability methods.
Published structure-activity studies, including systematic Ala-scanning by Cervini et al. conducted mainly on a [Nle27]-hGHRH(1-29)-NH2 scaffold (in which the native Met27 is replaced by norleucine), show that individual amino-acid substitutions can increase, reduce, or nearly eliminate activity in specific in-vitro assay systems. In that study, single-point alanine replacements at positions 8, 9, 15, 22, and 28 produced analogues 2–6 times more potent than the hGHRH(1-40)-OH standard, whereas alanine substitution at positions 1, 3, 5, 6, 10, 11, 13, 14, and 23 caused nearly complete loss of potency.[8]
Peptides should therefore be compared in the same assay instead of comparing values taken from unrelated studies.
How to Read a Certificate of Analysis
A certificate of analysis, or COA, should be read as a group of separate test results. HPLC purity, mass-spectrometry identity, peptide content, water, counterions, and residual solvents do not measure the same thing.
| COA Item | What It Shows | What It Does Not Show |
|---|---|---|
| Sequence or identity | The intended peptide name and amino-acid sequence | It does not confirm that the tested batch has the correct mass |
| Mass spectrometry | Whether the observed mass agrees with the expected peptide mass | It does not by itself measure total purity or peptide content |
| HPLC purity | The percentage of detected chromatographic peak area assigned to the main peptide under the stated method | It is not automatically the same as the amount of peptide in the vial |
| Peptide content | The amount or percentage of actual peptide in the material | It should not be assumed from gross vial weight alone |
| Water | The measured water present in the sample | It is not included in HPLC peptide-purity results |
| Counterion | The amount of acetate, trifluoroacetate, or another counterion | It is not the same as peptide impurity |
| Residual solvents | Solvents remaining from manufacturing or purification | They cannot be ruled out by peptide HPLC alone |
| Endotoxin, bioburden, or sterility | Results from separate microbiological tests, when performed | They are not shown by HPLC or mass spectrometry |
The European Medicines Agency guideline for synthetic peptides (EMA/CHMP/CVMP/QWP/367182/2025, effective 1 June 2026) treats peptide identity, related impurities, manufacturing impurities, specifications, and analytical control as separate quality areas.[9] Although this EMA guideline is written for synthetic peptides used in medicinal products rather than establishing mandatory specifications for all research-use materials, its distinction between identity, assay, peptide-related impurities, non-peptide impurities, and analytical controls is useful when interpreting a research-material COA.
ICH Q14 (effective 14 June 2024) also states that an analytical method should be suitable for its intended purpose and that important method conditions should be controlled.[10] This means that an HPLC purity value is meaningful only when the method and detection conditions are clearly stated.
Research materials do not have one universal HPLC purity requirement. The needed purity depends on the experiment.
The article should report the actual batch result instead of describing every batch as having the same purity.
Solubility and Stock Preparation
Sermorelin should not be given one fixed water-solubility value for all batches. Solubility can change with the salt form, counterion level, pH, buffer, ionic strength, peptide concentration, temperature, and other materials in the vial.
A small test should be carried out in the intended laboratory buffer before a full stock is prepared. The record should include the peptide form, material mass, solvent, final volume, pH, appearance, and any visible particles or precipitation.
When accurate concentration is important, gross vial mass should not automatically be treated as pure-peptide mass. If the COA reports peptide content as an as-is mass fraction or clearly states that it is expressed as free-peptide equivalent, the peptide-equivalent mass may be calculated as:
Peptide-equivalent mass = weighed material mass × stated peptide-content fraction
The reporting basis of the peptide-content result must be confirmed before the calculation above is used. If the result is reported on a dry, anhydrous, or salt-free basis, additional corrections for water, counterion, and the reporting basis are needed.
For solution preparation, the mass concentration and molar concentration should be treated as separate calculations:
Mass concentration = peptide-equivalent mass ÷ final solution volume
Molar concentration = peptide-equivalent mass ÷ selected molecular-weight basis ÷ final solution volume
The calculation should state whether the molecular-weight basis is the non-salt peptide (3,357.9 g/mol), the 1:1 acetate form (3,417.9 g/mol), or another batch-specific form. When peptide content is expressed as free-peptide equivalent, the free-peptide molecular weight should normally be used consistently.
These formulas are only for preparing laboratory assay solutions. They are not human or veterinary dosing formulas.
Storage and Stability
The batch COA or product data sheet should be followed first. When no validated batch condition is provided, a common conservative laboratory approach is to keep the lyophilized peptide sealed, dry, protected from light, and stored at about -20 °C.
This storage temperature does not prove that the material has an unlimited shelf life. A retest date or expiration date should be supported by stability data.
There is also no single storage time that applies to every prepared solution. Solution stability depends on the buffer, pH, concentration, temperature, oxygen exposure, container, and number of freeze-thaw cycles.
If stability matters to the experiment, intact peptide and breakdown products should be checked with a suitable HPLC or LC-MS method.
How Research Results Should Be Reported
Every biological statement should name the type of experiment. Useful wording includes “in a receptor-expressing cell assay,” “in cultured rat pituitary cells,” “in purified rat somatotrophs loaded with indo-1,” or “in a purified-enzyme study.”
This makes it clear what the study actually tested.
Cell activity, enzyme stability, HPLC purity, or results from a laboratory animal model do not by themselves prove human safety, clinical effectiveness, or suitability for personal use. This article therefore does not include human administration routes, body-weight doses, injection instructions, diagnostic cutoffs, treatment claims, or personal-use guidance.
Research References
- National Center for Biotechnology Information. PubChem Compound Summary for Sermorelin, CID 16132413.
https://pubchem.ncbi.nlm.nih.gov/compound/Sermorelinum - National Center for Biotechnology Information. PubChem Compound Record for Sermorelin Acetate, CID 16132412.
https://pubchem.ncbi.nlm.nih.gov/compound/16132412 - Ling N, Baird A, Wehrenberg WB, Ueno N, Munegumi T, Brazeau P. Synthesis and in vitro bioactivity of C-terminal deleted analogs of human growth hormone-releasing factor. Biochemical and Biophysical Research Communications. 1984;123(2):854-861.
https://pubmed.ncbi.nlm.nih.gov/6435620/ - Gaylinn BD, Harrison JK, Zysk JR, Lyons CE, Lynch KR, Thorner MO. Molecular cloning and expression of a human anterior pituitary receptor for growth hormone-releasing hormone. Molecular Endocrinology. 1993;7(1):77-84.
https://pubmed.ncbi.nlm.nih.gov/7680413/ - Lussier BT, French MB, Moore BC, Kraicer J. Free intracellular Ca2+ concentration and growth hormone release from purified rat somatotrophs. I. GH-releasing factor-induced Ca2+ influx raises intracellular Ca2+. Endocrinology. 1991;128(1):570-582. doi:10.1210/endo-128-1-570.
https://pubmed.ncbi.nlm.nih.gov/1846113/ - Frohman LA, Downs TR, Heimer EP, Felix AM. Dipeptidylpeptidase IV and trypsin-like enzymatic degradation of human growth hormone-releasing hormone in plasma. Journal of Clinical Investigation. 1989;83(5):1533-1540.
https://pubmed.ncbi.nlm.nih.gov/2565342/ - Bongers J, Lambros T, Ahmad M, Heimer EP. Kinetics of dipeptidyl peptidase IV proteolysis of growth hormone-releasing factor and analogs. Biochimica et Biophysica Acta. 1992;1122(2):147-153. doi:10.1016/0167-4838(92)90317-7.
https://pubmed.ncbi.nlm.nih.gov/1353684/ - Cervini LA, Donaldson CJ, Koerber SC, Vale WW, Rivier JE. Human growth hormone-releasing hormone hGHRH(1-29)-NH2: systematic structure-activity relationship studies. Journal of Medicinal Chemistry. 1998;41(5):717-727. doi:10.1021/jm970618s.
https://pubmed.ncbi.nlm.nih.gov/9513600/ - European Medicines Agency. Guideline on the Development and Manufacture of Synthetic Peptides (EMA/CHMP/CVMP/QWP/367182/2025, effective 1 June 2026).
https://www.ema.europa.eu/en/development-manufacture-synthetic-peptides-scientific-guideline - European Medicines Agency. ICH Q14 Guideline on Analytical Procedure Development (EMA/CHMP/ICH/195040/2022, effective 14 June 2024).
https://www.ema.europa.eu/en/ich-q14-analytical-procedure-development-scientific-guideline
Research Use Only Disclaimer
Research Use Only: The product described on this page is for laboratory research purposes only and not FDA-approved for human use. This guide/article is provided for informational context regarding standard laboratory research contexts only, and does not constitute medical, clinical, veterinary guidance or treatment advice.